Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Current and Emerging Clinical Strategies for Pancreatic Cancer Treatment
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: March 11, 2021 Expiration: March 10, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.
Michael J. Pishvaian, MD, PhD
Rachna Shroff, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply individualized treatment strategies for the selection and sequencing of therapies for localized and advanced pancreatic cancer
  • Examine the role of PARP inhibitor maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed pancreatic cancer and a germline BRCA mutation
  • Appraise the rationale and available/emerging data for the use of emerging and investigational therapies (novel chemotherapy platforms, PARP inhibitor, immunotherapy [and immunotherapy-based combinations], stroma-targeting agents, tumor treating fields therapy, and others) and integrate into treatment planning as clinically applicable
  • Incorporate strategies to effectively identify and manage disease-related and treatment-related adverse events to support quality of life and continuation of therapy

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Michael J. Pishvaian, MD, PhD

Associate Professor
Department of Gastrointestinal Medical Oncology
Co-director for Clinical Research
Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael J. Pishvaian, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Merck, and Seattle Genetics and has ownership interest in Perthera.
Rachna Shroff, MD

Assistant Professor of Medicine
Chief
, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna T. Shroff, MD, has disclosed that she has received consulting fees from Agios/Clovis, Debiopharm, Exelixis, Incyte, Merck, QED Therapeutics, and Seattle Genetics and funds for research support from Exelixis, Merck, Pieris, Rafael, and Taiho.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists, radiation oncologists, surgical oncologists, and other healthcare providers who treat patients with pancreatic cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with pancreatic cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 11, 2021, through March 10, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Current and Emerging Clinical Strategies for Pancreatic Cancer Treatment
  • CME
  • MOC

Loading...
In this on-demand Webcast from a live Webinar, expert faculty discuss best practices in treating patients with resectable and advanced pancreatic cancer and provide a look ahead at emerging therapeutic strategies that may soon change practice.
Michael J. Pishvaian, MD, PhD
Rachna Shroff, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: March 11, 2021 Expiration: March 10, 2022

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for advanced HCC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for early HCC and advanced BTC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

Adjuvant nivolumab prolonged DFS in patients with resected EC/GEJC who had received neoadjuvant chemotherapy compared with placebo; from ASCO as reported by Clinical Care Options (CCO)

Released: June 17, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue